Journal of Neuro-Oncology

, Volume 53, Issue 1, pp 39-46

First online:

Preliminary Results of Active Specific Immunization with Modified Tumor Cell Vaccine in Glioblastoma Multiforme

  • Thomas SchneiderAffiliated withDepartment of Neurosurgery, Otto-von-Guericke University
  • , Roswitha GerhardsAffiliated withInstitute of Experimental Oncology, Marienhospital
  • , Elmar KirchesAffiliated withDepartment of Neuropathology, Otto-von-Guericke University
  • , Raimund FirschingAffiliated withDepartment of Neurosurgery, Otto-von-Guericke University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Object Treatment for glioblastoma multiforme has failed to show any progress for decades. While specific immunization with tumor cells modified with Newcastle-Disease-Virus (NDV) has been reported successful in some extracerebral tumors, its effect on glioblastoma is unknown. We report on 11 patients, in whom this approach was analyzed.

Methods A vaccine was produced from autologous tumor cell cultures of 11 patients with glioblastoma. After completed surgery and radiotherapy an intracutaneous vaccination was performed 4 times with a 2 week interval and finally after 3 months. Local reactions, general side effects and survival were monitored closely.

Results The local reaction of the skin after injection of vaccine increased from 1.67 to 4.05 cm2 in 8 weeks. The skin reaction after parallel injection of inactivated, untreated tumor cells increased from 0.11 to 1.09 cm2. The median survival was 46 weeks (mean 60 weeks). No side effects were noted.

Conclusion Active specific immunization with NDV-modified glioblastoma cells produced a noticeable peripheral immune response. In this preliminary series survival of patients was not significantly longer after active specific immunization than after combined treatment of surgery, radiotherapy and chemotherapy. As there were no side effects, however, active specific immunization may be nobreak considered an alternative in the management of glioblastoma.

immunization specific immunotherapy glioblastoma NDV